Smith & Nephew plc
United Kingdom · GB0009223206 · reports in USD · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +6.1% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 12% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 51% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in USD.
$6.2B
revenue
13%
operating margin
$625M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | $5.2B | $5.5B | $5.8B | $6.2B |
| Operating profit | $450M | $425M | $657M | $794M |
| Earnings per share | $0.26 | $0.30 | $0.47 | $0.72 |
| Cash from operations | $468M | $608M | $987M | $1.3B |
| Cash | $344M | n/a | $619M | $557M |
| Total assets | $10.0B | n/a | $10.4B | $10.5B |
| Equity | $5.3B | $5.2B | $5.3B | $5.3B |
What they do
In the company's own words, from the annual report.
develop, manufacture, market and sell medical devices and services.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.